engleski

The role of F-18-choline PET/CT in prostate cancer patients staging

Introduction: The aim of this study was to evaluate the value of F-18 choline PET/CT in the initial staging of high-risk prostate cancer patients. Subjects and methods: Hundred consecutive biopsy-confirmed prostate cancer patients were scanned with F-18-choline PET/CT from February 2012 to April 2018. Mean PSA value at referral was 48.4 ng/ml (range 4.3 to 280.6 ng/ml). Functional imaging was proposed in high- risk patients after equivocal conventional imaging and bone scintigraphy findings. Imaging was performed after administration of F-18 choline (2– 3 MBq/kg, mean 209MBq). All patients had a minimum 6-month follow-up. Results: There were 24 patients without metastases, while the majority of patients (76%) had a choline scan positive for metastatic disease. Eight patients had a single positive pelvic lymph node, with a short axis diameter shorter than 1cm. 56 patients had FCH positive metastatic disease in lymph nodes only (mean SUV 6.4), 25 in lymph nodes and/or skeleton (mean SUV 10.7). In sixteen patients seminal vesicles’ infiltration was found. Majority of our patient population had a combination of radiotherapy and hormonal therapy, with the mean PSA levels after six months significantly lower (2.1 ng/ml). Conclusion: F-18-choline PET/CT provides clinicians with valuable information in the staging of high-risk prostate cancer. It has an important impact on therapeutic strategy, providing additional data necessary for the appropriate and individual patient management.

F-18-choline ; staging ; prostate cancer

nije evidentirano